AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 14 - (NewsRx.com & NewsRx.net) -- Nucletron Corp. announced that the U.S. Food and Drug Administration has cleared the Kuske Breast Template, a device used to give physicians precision guidance during interstitial accelerated partial breast irradiation (APBI).
Interstitial APBI used with the Kuske Breast Template, the company claims, will help standardize the procedure and greatly enhance the accuracy of High Dose Rate (HDR) breast brachytherapy procedures, allowing patients to be effectively treated in 4-5 days rather than the typical 5-7 weeks of treatment with external beam radiation. Long-term follow-up from studies conducted by Dr. Robert Kuske, Jr., using large-volume HDR brachytherapy implants for breast cancer have shown a less than 2% local recurrence rate in nearly 300 women treated over the last 11 years.
The Kuske Breast Template was developed by Kuske, professor or Human Oncology at the University of Wisconsin in conjunction with Nucletron Corporation.
"The Template improves our ability to target and control the radiation delivered to the tumor site with more uniformity, treating only the cancerous cells and sparing healthy breast tissue," said Kuske, who ...
Source: HighBeam Research, FDA clears new breast brachytherapy device.(Food and Drug...